Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence

Trends in Pharmacological Sciences

Volumn 37, Issue 2, 2016, Pages 120-142

  De Flora, Silvio ^a   Ganchev, Gancho ^b   Iltcheva, Marietta ^b   La Maestra, Sebastiano ^a   Micale, Rosanna T ^a   Steele, Vernon E ^c   Balansky, Roumen ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b National Oncology Center Bulgaria   (Bulgaria)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

anti inflammatory drugs; antidiabetic drugs; antineoplastic drugs; cigarette smoke; lung cancer; pharmacological prevention

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ASCORBIC ACID; BEXAROTENE; BUDESONIDE; CELECOXIB; INOSITOL; LAPATINIB; LICOFELONE; METFORMIN; NAPROXEN; PHENETHYL ISOTHIOCYANATE; PIOGLITAZONE; VORINOSTAT; ANTINEOPLASTIC AGENT;

CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG STRUCTURE; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; ANIMAL; CARCINOGENESIS; DISEASE MODEL; DRUG EFFECTS; LUNG NEOPLASMS; PREVENTION AND CONTROL; SMOKING CESSATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; SMOKING; SMOKING CESSATION;

EID: 84955443140     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.11.003     Document Type: Review

References (144)

1. International Agency for Research on Cancer A Review of Human Carcinogens: Personal Habits and Indoor Combustions (IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 100E) 2012 IARC
2. S. De Flora, and et al. Rationale and approaches to the prevention of smoking-related diseases: Overviews of recent studies on chemoprevention of smoke-induced tumors in animal models J. Environ. Sci. Health C: Environ. Carcinog. Ecotoxicol. Rev. 32 2014 105 120
3. P. Kanavos The rising burden of cancer in the developing world Ann. Oncol. 17 Suppl. 8 2006 viii15 viii23
4. S. De Flora, and et al. Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis Mutat. Res. 523/524 2003 237 252
5. S. De Flora, and et al. Smoke-induced microRNA and proteome alterations and their modulation by chemopreventive agents Int. J. Cancer 131 2012 2763 2773
6. S.S. Hecht Lung carcinogenesis by tobacco smoke Int. J. Cancer 131 2012 2724 2732
7. H. Witschi A/J mouse as a model for lung tumorigenesis caused by tobacco smoke: strengths and weaknesses Exp. Lung Res. 31 2005 3 18
8. S.S. Hecht Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new Carcinogenesis 26 2005 1488 1492
9. J.A. Hutt, and et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways Carcinogenesis 26 2005 1999 2009
10. W. Stinn, and et al. Towards the validation of a lung tumorigenesis model with mainstream cigarette smoke inhalation using the A/J mouse Toxicology 305 2013 49 64
11. S. De Flora, and et al. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke Cancer Res. 63 2003 793 800
12. A. Izzotti, and et al. Birth related genomic and transcriptional changes in mouse lung. Modulation by transplacental N-acetylcysteine Mutat. Res. Rev. 544 2003 441 449
13. R. Balansky, and et al. Potent carcinogenicity of cigarette smoke in mice exposed early in life Carcinogenesis 28 2007 2236 2243
14. R. Balansky, and et al. Differential carcinogenicity of cigarette smoke in mice exposed either transplacentally, early in life or in adulthood Int. J. Cancer 130 2012 1001 1010
15. S.S. Hecht, and E. Szabo Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer Cancer Prev. Res. 7 2014 1 8
16. S. De Flora, and L.R. Ferguson Overview of mechanisms of cancer chemopreventive agents Mutat. Res. 591 2005 8 15
17. E. Szabo, and et al. Chemoprevention of lung cancer Chest 143 Suppl. 2013 e40S e60S
18. K. Dragnev, and et al. Lung cancer chemoprevention: difficulties, promise and potential agents? Expert Opin. Investig. Drugs 22 2013 35 47
19. S.H. Sheth, and et al. Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions Oral Oncol. 51 2015 557 564
20. S.S. Hecht, and et al. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers Nat. Rev. Cancer 9 2009 476 488
21. E.R. Kasala, and et al. Benzo(a)pyrene- induced lung cancer: role of dietary phytochemicals in chemoprevention Pharmacol. Rep. 67 2015 996 1009
22. R. Balansky, and et al. Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice Arch. Toxicol. 2015 10.1007/s00204-015-1550-5 Published online June 24, 2015
23. E.P. O'Donnell, and et al. Quantitative analysis of early chemically induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis Cancer Lett. 241 2006 197 202
24. A.Y. Nikitin, and et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium Cancer Res. 64 2015 2307 2316
25. R. Balansky, and et al. Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice Carcinogenesis 30 2009 1398 1401
26. R. Balansky, and et al. Transplacental antioxidants inhibit lung tumors in mice exposed to cigarette smoke after birth: a novel preventative strategy? Curr. Cancer Drug Targets 12 2012 164 169
27. A. Izzotti, and et al. Modulation by metformin of molecular and histopathological alterations in the lung of cigarette smoke-exposed mice Cancer Med. 3 2014 719 730
28. B.B. Aggarwal, and et al. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72 2006 1605 1621
29. S.I. Grivennikov, and et al. Immunity, inflammation, and cancer Cell 140 2010 883 899
30. H. Takahashi, and et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation Cancer Cell 17 2010 89 97
31. V.H. van der Velden Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma Mediators Inflamm. 7 1998 229 237
32. D. Mazhar, and et al. COX and cancer QJM 98 2005 711 718
33. F. Wolfe, and et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy J. Rheumatol. 29 2002 467 473
34. R.E. Harris Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer Subcell. Biochem. 42 2007 93 126
35. I.T. Lee, and C.M. Yang Inflammatory signalings involved in airway and pulmonary diseases Mediators Inflamm. 2013 2013 791231
36. L.W. Wattenberg, and et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol Carcinogenesis 21 2000 179 182
37. R. Balansky, and et al. Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: chemoprevention by budesonide and N-acetylcysteine Proc. Natl. Acad. Sci. U.S.A. 103 2006 7823 7828
38. R. Balansky, and et al. Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine Int. J. Cancer 126 2010 1047 1054
39. R.D. Estensen, and et al. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice Carcinogenesis 25 2004 197 201
40. S.M. Fischer, and et al. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention Cancer Prev. Res. 4 2011 1728 1735
41. A. Koul, and N. Arora Celecoxib mitigates cigarette smoke induced oxidative stress in mice Indian J. Biochem. Biophys. 47 2010 285 291
42. L.R. Kisley, and et al. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice Carcinogenesis 23 2002 1653 1660
43. R.E. Harris, and et al. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study Int. J. Biol. Sci. 3 2007 328 334
44. J.T. Mao, and et al. Lung cancer chemoprevention with celecoxib in former smokers Cancer Prev. Res. 4 2011 984 993
45. A.J. Duffield-Lillico, and et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway Cancer Prev. Res. 2 2009 322 329
46. G.J. Tranah, and et al. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study Mol. Carcinog. 44 2005 21 30
47. N.M. Davies, and et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor Clin. Pharmacokinet. 38 2000 225 242
48. J. Cuzick, and et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol. 10 2009 501 507
49. G. Jalbert, and A. Castonguay Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice Cancer Lett. 66 1992 21 28
50. R.K. Saini, and S.N. Sanyal Chemopreventive effect of nonsteroidal anti-inflammatory drugs on 9,10-dimethylbenz[a]anthracene induced lung carcinogenesis in mice Oncol. Res. 17 2009 505 518
51. C. Bosetti, and et al. Aspirin and cancer risk: a summary review to 2007 Recent Results Cancer Res. 181 2009 231 251
52. P.M. Rothwell, and et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
53. S. La Maestra, and et al. Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth Carcinogenesis 36 2015 1531 1538
54. S.I. Meireles, and et al. Early changes in gene expression induced by tobacco smoke: evidence for the importance of estrogen within lung tissue Cancer Prev. Res. 3 2010 707 717
55. J. Peng, and et al. Estrogen metabolism within the lung and its modulation by tobacco smoke Carcinogenesis 34 2013 909 915
56. L.P. Stabile, and J.M. Siegfried Estrogen receptor pathways in lung cancer Curr. Oncol. Rep. 6 2004 259 267
57. M.B. Terry, and et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk JAMA 291 2004 2433 2440
58. M. Xie, and et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status PLoS ONE 9 2014 e90286
59. J.M. Alvaro-Gracia Licofelone - clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis Rheumatology 43 Suppl. 1 2004 i21 i25
60. S. Sharma, and et al. Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration Cancer Prev. Res. 4 2011 1233 1242
61. R. Balansky, and et al. Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke Curr. Cancer Drug Targets 15 2015 188 195
62. S. Fiorucci, and et al. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 62 2001 1433 1438
63. M.J. Tsai, and et al. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner Lung Cancer 86 2014 137 143
64. R.M. Memmott, and et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis Cancer Prev. Res. 3 2010 1066 1076
65. E. Giovannucci, and et al. Diabetes and cancer: a consensus report Diabetes Care 33 2010 1674 1685
66. C. Willi, and et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis JAMA 298 2007 2654 2664
67. C.V. Rizos, and M.S. Elisaf Metformin and cancer Eur. J. Pharmacol. 705 2013 96 108
68. R.J. Shaw, and et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 310 2005 1642 1646
69. A. Decensi, and et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev. Res. 3 2010 1451 1461
70. H. Noto, and et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS ONE 7 2012 e33411
71. R.J. Stevens, and et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 2593 2603
72. D. Soranna, and et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 2012 813 822
73. Z.J. Zhang, and et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis Am. J. Epidemiol. 180 2014 11 14
74. G. Libby, and et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
75. M. Bodmer, and et al. Metformin does not alter the risk of lung cancer: a case-control analysis Lung Cancer 78 2012 133 137
76. I.G. Popovich, and et al. Metformin effect on urethane-induced tumorigenesis in mice Vopr. Onkol. 58 2012 549 553
77. Y.R. Ma, and et al. Gender-related differences in the expression of organic cation transporter 2 and its role in urinary excretion of metformin in rats Eur. J. Drug Metab. Pharmacokinet. 2015 10.1007/s13318-015-0278-1 Published online April 17, 2015
78. V.N. Anisimov, and et al. Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin Cell Cycle 14 2015 46 55
79. A. Zieleniak, and et al. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma Arch. Immunol. Ther. Exp. 56 2008 331 345
80. F. Ondrey Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention Clin. Cancer Res. 15 2009 2 8
81. A. Rubenstrunk, and et al. Safety issues and prospects for future generations of PPAR modulators Biochim. Biophys. Acta 1771 2007 1065 1081
82. H. Li, and et al. Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis PLoS ONE 6 2011 e28133
83. A. Izzotti, and et al. Relationships between pulmonary microRNA and proteome profiles, systemic cytogenetic damage, and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents Carcinogenesis 34 2013 2322 2329
84. S. La Maestra, and et al. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents Carcinogenesis 34 2013 183 189
85. C. Bosetti, and et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis Oncologist 18 2013 148 156
86. J.F. Hardisty, and et al. Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists Toxicol. Pathol. 36 2008 769 776
87. K. Sato, and et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats Toxicol. Appl. Pharmacol. 251 2011 234 244
88. P.J. Medina, and S. Goodin Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 30 2008 1426 1447
89. S. Filosto, and et al. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors Mol. Cancer Ther. 11 2012 795 804
90. L. Landi, and F. Cappuzzo HER2 and lung cancer Expert Rev. Anticancer Ther. 13 2013 1219 1228
91. R. Diaz, and et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model BMC Cancer 10 2010 188
92. H.J. Ross, and et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer Clin. Cancer Res. 16 2010 1938 1949
93. R. Balansky, and et al. Assay of lapatinib in murine models of cigarette smoke carcinogenesis Carcinogenesis 35 2014 2300 2307
94. P.A. Marks Discovery and development of SAHA as an anticancer agent Oncogene 26 2007 1351 1356
95. T. Hayashi, and et al. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus Cancer Res. 65 2005 9771 9778
96. A. Edwards, and et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells Mol. Cancer Ther. 6 2007 2515 2524
97. N. Reguart, and et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression Lung Cancer 84 2014 161 167
98. 18F-FAHA PET/CT imaging of NNK-treated A/J mice model Am. J. Nucl. Med. Mol. Imaging 4 2014 324 332
99. B.C. Casto, and M.A. Pereira Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration Anticancer Res. 31 2011 3279 3284
100. K. Tran, and et al. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer Carcinogenesis 34 2013 199 210
101. Y. Wang, and et al. Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide Mol. Cancer Ther. 5 2006 1060 1072
102. J.B. Budgin, and et al. Biological effects of bexarotene in T cell lymphoma Arch. Dermatol. 141 2005 315 321
103. K.H. Dragnev, and et al. Nonclassical retinoids and lung carcinogenesis Clin. Lung Cancer 6 2005 237 244
104. M.A. Pereira, and et al. Prevention of mouse lung tumors by targretin Int. J. Cancer 118 2006 2359 2362
105. O. Ziouzenkova, and J. Plutzky Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex FEBS Lett. 582 2008 32 38
106. K. Tachibana, and et al. The role of PPARs in cancer PPAR Res. 2008 2008 102737
107. S.S. Hecht Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention Lancet Oncol. 3 2002 461 469
108. A. Izzotti, and et al. Modulation of multigene expression and proteome profiles by chemopreventive agents Mutat. Res. 591 2005 212 223
109. F. D'Agostini, and et al. Modulation of apoptosis by chemopreventive agents Mutat. Res. 591 2005 173 186
110. H. Witschi, and et al. The effects of phenethyl isothiocyanate, N-acetylcysteine and green tea on tobacco smoke-induced lung tumors in strain A/J mice Carcinogenesis 19 1998 1789 1794
111. L.W. Wattenberg Chemoprevention of pulmonary carcinogenesis by myo-inositol Anticancer Res. 19 1999 3659 3661
112. S.S. Hecht, and et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination Carcinogenesis 23 2002 1455 1461
113. W.T. Gunning, and et al. Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice Exp. Lung Res. 26 2000 757 772
114. S. De Flora, and et al. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points Carcinogenesis 22 2001 999 1013
115. N. van Zandwijk, and et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups J. Natl. Cancer Inst. 92 2000 977 986
116. F.J. Van Schooten, and et al. Effects of oral N-acetylcysteine: a multi-biomarker study in smokers Cancer Epidem. Biomarkers Prev. 11 2002 167 175
117. S. De Flora, and et al. Smokers and urinary genotoxins. Implications for selection of cohorts and modulation of endpoints in chemoprevention trials J. Cell Biochem. Suppl. 25 1996 92 98
118. S. De Flora, and et al. Inhibition of urethan-induced lung tumors in mice by dietary N-acetylcysteine Cancer Lett. 32 1986 235 241
119. R.M. Balansky, and S. De Flora Chemoprevention by N-acetylcysteine of urethane-induced clastogenicity and lung tumors in mice Int. J. Cancer 77 1998 302 305
120. F. D'Agostini, and et al. Interactions between N-acetylcysteine and ascorbic acid in modulating mutagenesis and carcinogenesis Int. J. Cancer 88 2000 702 707
121. F.L. Chung, and et al. Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats Cancer Res. 56 1996 772 778
122. C.C. Conaway, and et al. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice Cancer Lett. 124 1998 85 93
123. H. Witschi Carcinogenic activity of cigarette smoke gas phase and its modulation by beta-carotene and N-acetylcysteine Toxicol. Sci. 84 2005 81 87
124. H. Witschi, and et al. The carcinogenic potential of the gas phase of environmental tobacco smoke Carcinogenesis 18 1997 2035 2042
125. A. Izzotti, and et al. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light FASEB J. 23 2009 3243 3250
126. T. Cai, and et al. N-Acetylcysteine inhibits endothelial cell invasion and angiogenesis while protecting from apoptosis Lab. Invest. 79 1999 1151 1159
127. A. Albini, and et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine Cancer Res. 61 2001 8171 8178
128. B. Frei, and et al. Ascorbate is an outstanding antioxidant in human blood plasma Proc. Natl. Acad. Sci. U.S.A. 86 1989 6377 6381
129. T.K. Yun, and et al. Trial of a new medium-term model using benzo(a)pyrene induced lung tumor in newborn mice Anticancer Res. 15 1995 839 845
130. M. Cortés-Jofré, and et al. Drugs for preventing lung cancer in healthy people Cochrane Database Syst. Rev. 10 2012 CD002141
131. N.P. Seeram Berry fruits for cancer prevention: current status and future prospects J. Agric. Food Chem. 56 2008 630 635
132. G.D. Stoner, and et al. Cancer prevention with freeze-dried berries and berry components Semin. Cancer Biol. 17 2007 403 410
133. R. Balansky, and et al. Inhibition of lung tumor development by berry extracts in mice exposed to cigarette smoke Int. J. Cancer 131 2012 1991 1997
134. P.S. Carlton, and et al. Failure of dietary lyophilized strawberries to inhibit 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene-induced lung tumorigenesis in strain A/J mice Cancer Lett. 159 2000 113 117
135. J.M. Siegfried Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis Cancer Prev. Res. 3 2010 692 695
136. H.S. Aiyer, and R.C. Gupta Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism Cancer Prev. Res. 3 2010 727 737
137. E. Schmitt, and H. Stopper Estrogenic activity of naturally occurring anthocyanidins Nutr. Cancer 41 2001 145 149
138. M. Larrosa, and et al. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities J. Agric. Food Chem. 54 2006 1611 1620
139. S. De Flora, and A. Izzotti Modulation of genomic and postgenomic alterations in noncancer diseases and critical periods of life Mutat. Res. 667 2009 15 26
140. S.C. Gupta, and et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs Trends Pharmacol. Sci. 34 2013 508 517
141. R.L. Keith, and Y.E. Miller Lung cancer chemoprevention: current status and future prospects Nat. Rev. Clin. Oncol. 10 2013 334 343
142. D.J.P. Barker Maternal nutrition, fetal nutrition, and diseases in later life Nutrition 13 1997 807 813
143. L.M. Anderson Introduction and overview. Perinatal carcinogenesis: growing a node for epidemiology, risk management, and animal studies Toxicol. Appl. Pharmacol. 199 2004 85 90
144. T.E. Burns, and L.P. Stabile Targeting the estrogen pathway for the treatment and prevention of lung cancer Lung Cancer Manag. 3 2014 43 52